Risankizumab

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, recaps results from the SEQUENCE trial, which were presented at Digestive Disease Week 2024.

WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 KNOCKOUT study.

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the phase 2 KNOCKOUT study presented at the American Academy of Dermatology Annual Meeting.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor risankizumab from the Maui Derm 2024 meeting.

LAS VEGAS —A presenter at the Crohn’s & Colitis Congress outlined some of the newer therapies that have expanded the current “arsenal of tools” for the treatment of inflammatory bowel disease.

VANCOUVER, British Columbia — In a Healio video exclusive, Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial, in which more patients with ulcerative colitis achieved clinical remission on IV risankizumab vs. placebo.

NEW YORK — Skyrizi exhibited efficacy across racial and ethnic groups for the treatment of moderate to severe plaque psoriasis, according to a presentation at the Skin of Color Update 2023 meeting.

After 1 year of continuous use, risankizumab helped patients with moderate to severe plaque psoriasis achieve skin clearance regardless of prior biologic usage, according to a real-world study.

Risankizumab demonstrated a consistent long-term safety profile and clinical response in patients with moderate to severe plaque psoriasis, according to a phase 3 study.